Annexon (ANNX) Current Deferred Revenue (2019 - 2021)

Annexon (ANNX) posted quarterly Current Deferred Revenue of $398000.0 for Q1 2021, up 1.79% quarter-over-quarter from $391000.0 in Q4 2020.

Annexon (ANNX) Current Deferred Revenue (2019 - 2021) Analysis & Trends

Annexon's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $398000.0 for Q1 2021.

In Q1 2021, Current Deferred Revenue changed N/A year-over-year to $398000.0; the TTM figure through Mar 2021 stood at $398000.0 (changed N/A YoY), while the FY2020 annual figure was $391000.0, up 6.83% from the prior year.
Current Deferred Revenue for Q1 2021 stood at $398000.0, up from $391000.0 in the prior quarter.
The five-year high for Current Deferred Revenue was $398000.0 in Q1 2021, with the low at $366000.0 in Q4 2019.
The 3-year median for Current Deferred Revenue is $385000.0 (2020), against an average of $383600.0.
Peak annual rise in Current Deferred Revenue reached 6.83% in 2020, while the deepest fall reached 6.83% in 2020.
Annexon's Current Deferred Revenue stood at $366000.0 in 2019, then rose by 6.83% to $391000.0 in 2020, then gained by 1.79% to $398000.0 in 2021.
Business Quant data shows ANNX's Current Deferred Revenue at $398000.0 in Q1 2021, $391000.0 in Q4 2020, and $385000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Annexon	1.00 Bn	1.00 Bn	-

Download Data